PTC Therapeutics (PTCT) Misses Q1 EPS by 3c

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $56.72 million.

GUIDANCE:

PTC Therapeutics sees Q2 2018 net product revenue of $260-295 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• AeroVironment restates quarterly financials, citing $89M goodwill error